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Letter to editor Click here to view linked References
Dear Editor, 
Recent articles in this Journal have suggested the potential of antigen-based rapid diagnostic tests (Ag-
RDT) as low-cost and ease-of-use tools for massive screening and epidemiological surveillance of SARS-
CoV-2 spread.1,2 Based on a pre-screening of four Ag-RDT on 40 frozen specimens from nasopharyngeal 
swabs with known PCR results (Table S1, Appendix), we selected the Panbio COVID-19 Ag Test (Abbott) 
for investigating its analytical and clinical performance. 
The analysis of serial dilutions of a SARS-CoV-2 isolate, propagated in Vero E6 cells, yielded a limit of 
detection (LoD) of 6.5 × 105 genome copies/reaction (Table S2). According to this value, the test would 
not detect SARS-CoV-2 infection in respiratory specimens with very low viral load. Still, the LoD was one 
logarithmic unit below the 106 copies/mL threshold necessary for successful virus isolate from respiratory 
samples.3 
The clinical performance was analysed on frozen swabs from 1,406 individuals (mean age 40.4 years; SD 
24.5) with an RT-qPCR result available: 951 (67.6%) positive and 455 (32.4%) negative. Overall, 446 
(31.7%) and 473 (33.6%) samples were nasopharyngeal swabs from symptomatic individuals and contacts 
exposed to symptomatic cases, respectively, and 487 (34.6%) were nasal mid-turbinate swabs from 
asymptomatic individuals collected in screening campaigns. The cycle threshold (Ct) of PCR-positive 
samples was <20, 20–24, 25–29, and >30 in 258 (17.1%), 305 (32.1%), 285 (30.0%), and 103 (10.8%), 
respectively (median Ct 23.6; interquartile range 19.7–27.3).  
Overall, the Ag-RDT identified the presence of SARS-CoV-2 in 872 of 951 PCR-positive samples 
(sensitivity 91.7%; 95% CI 89.8–93.4) and ruled out its presence in 450 of 455 PCR-negative samples 
(specificity 98.9%; 97.5–99.6)(Table S3). In line with previous reports of clinical performance of this test,2 
sensitivity increased with lower Ct values (Ct <25, 98.2%; Ct<30, 94.9%) and was higher among samples 
collected in the setting of case identification (92.6%) and contact tracing (94.2%) than asymptomatic 
screening (79.5%). The increasing trend of sensitivity with lower Ct values was maintained in the setting 
of asymptomatic screening: sensitivity of samples with Ct <25 and <30 were 100% and 98.6%, respectively 
(Figure 1). The high sensitivity of the Ag-RDT in samples with low Ct values, which was consistent with 
the LoD, has important implications for using this test as an epidemiological surveillance tool. A growing 
body of evidence indicates that PCR-positive respiratory specimens with low viral load (i.e., Ct >25 or <106 
copies/mL) have a limited capacity for effective transmission.3,4 Also, studies based on contact tracing 
strategies showed that the secondary attack rate significantly increases among index cases with Ct values 
<25.5 The higher sensitivity of the Ag-RDT in samples with low Ct, irrespective of the presence of 
symptoms, indicates that the test is particularly suitable for identifying individuals who are contagious. 
Like most studies investigating the clinical performance of RDTs,6  our assessment was retrospectively on 
frozen samples from three different settings. Our internal validation showed no relevant differences 
between tests performed on fresh samples using the Abbot test Kit buffer and 1:3 dilutions of the Kit buffer 
and frozen specimens stored on transport media. Although we encourage internal validation before using 
this approach, our experience suggests the suitability of parallel sampling for Ag-RDT and PCR tests. 
Another consequence of not sampling in the intended setting was the impossibility of direct estimates of 
the positive predictive value (PPV) and negative predictive value (NPV). Alternatively, we modelized the 
PPV and NPV assuming a wide range of prevalence (i.e., pre-test probability) in the target population 
(Figure 2). At a pre-test probability of 5%, consistent with the prevalence observed in asymptomatic 
screening campaigns in high-risk settings,7 the NPV was 99.6% (99.5–99.7) (Table S4) and increased as 
the pre-test probability dropped. Correspondingly, the PPV at 5% pre-test probability was 81.5% (65.0–
93.2) and decreased as pre-test probability decreased. At 5% pre-test probability, the estimated number of 
false-negative and false-positive values per thousand tests were 4 (3–5) and 12 (4–27), respectively 
(TableS5).  
Our analytical and clinical performance findings suggest that the Ag-RDT cannot replace nucleic acid 
amplification tests (NAAT) as a tool to confirm or rule out the presence of SARS-CoV-2. However, the 
high sensitivity of NAAT has raised questions as to the clinical and epidemiological meaning of being 
positive for SARS-CoV-2 infection. In some patients, low levels of viral RNA can remain detectable by 
RT-qPCR for months, with doubtful transmission capacity. The Ag-RDT reliably identifies people with 
high viral loads, and therefore it could be useful for screening strategies to identify and isolate asymptomatic 
COVID-19 people while they are still infectious. Although the kinetics of SARS-CoV-2 have not been well 
established, current evidence suggests that this time window may begin approximately four days after 
exposure and last for nearly ten days.8 Of note, during the exponential phase, viral RNA may rise from 
undetectable levels (i.e., Ct >40) to millions of RNA copies/mL (i.e., Ct < 25) in the order of a day,9 thus 
limiting the temporal validity of a negative result. 
Currently, the WHO recommends using Ag-RDTs to support the diagnosis of cases and contacts during 
outbreak investigations and monitor trends in disease incidence, particularly in remote settings or closed 
groups (e.g., schools, care homes, or prisons), but not to screen asymptomatic populations.10 However, our 
findings suggest that Ag-RDT might be useful for screening asymptomatic individuals, particularly in 
communities with high prevalence. Furthermore, the high sensitivity for detecting infected individuals with 
transmission capacity makes the test suitable for creating safe environments in time-limited social activities 
with high-risk of transmission, including―but not limited to―visiting relatives at nursing homes, playing 
sports, going to a crowded place like movie theatres, music concerts, and airports. 
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Figure 1. SARS-CoV-2 detection using the Ag-RDT Panbio COVID-19 Ag-Test on PCR-positive samples 
according to rt-qPCR Ct value.  
Sensitivity (95CI) of the Ag-RDT according to the disease status and RT-qPCR Ct value.  
 
Figure 2. Modelling of positive predictive value (PPV) and negative predictive value (NPV) assuming 
different pre-test probabilities. Dots represent the PPV and NPV at sequential increment of 0.01; lines are 
the 95% confidence interval. 
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